Summary

Join us for a timely and informative West Coast-timed webinar on HER2-Low and Ultralow Metastatic Breast Cancer: Evolving Definitions, Emerging Evidence, and Shifting Treatment Paradigms, featuring internationally recognized breast medical oncologist Dr. Aditya Bardia, who will share the latest insights and clinical trial data shaping global practice. Offering the Canadian perspective is Dr. Mita Manna, a respected breast cancer expert based in Western Canada, who will moderate the session and explore how these evolving advances are being integrated into clinical care across the region. Don't miss this opportunity to gain valuable guidance on navigating the changing landscape of HER2-low and ultralow disease.


This activity has been funded by an educational grant from AstraZeneca and Daiichi Sankyo and is intended for healthcare practitioners only.

Highlights

  • 1

    To provide an update on recent clinical trial results involving patients with HER2-low and HER2-ultralow metastatic breast cancer, highlighting key findings from both global and Canadian research efforts.

  • 2

    To put into clinical perspective advances in the treatment of these subtypes and the evolving treatment paradigm, with a focus on applicability in Canadian clinical practice alongside international trends.

  • 3

    To provide an overview of definitions of HER2-low, HER2-ultralow, and HER2-negative metastatic breast cancer, incorporating both international and Canadian classifications and diagnostic considerations.

User

Aditya Bardia, MD, MPH, FASCO

Professor, Dept. of Medicine, Division of Hematology/Oncology, UCLA Health

Medical Oncologist, Saskatoon Cancer Centre, Saskatchewan Cancer Agency

User

Mita Manna, MD, FRCPC

Comments (0)